A gelatin/collagen/polycaprolactone scaffold for skin regeneration. 2019

Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
Division of Plastic and Reconstructive Surgery, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan, R.O.C.

BACKGROUND A tissue-engineered skin substitute, based on gelatin ("G"), collagen ("C"), and poly(ε-caprolactone) (PCL; "P"), was developed. METHODS G/C/P biocomposites were fabricated by impregnation of lyophilized gelatin/collagen (GC) mats with PCL solutions, followed by solvent evaporation. Two different GC:PCL ratios (1:8 and 1:20) were used. RESULTS Differential scanning calorimetry revealed that all G/C/P biocomposites had characteristic melting point of PCL at around 60 °C. Scanning electron microscopy showed that all biocomposites had similar fibrous structures. Good cytocompatibility was present in all G/C/P biocomposites when incubated with primary human epidermal keratinocytes (PHEK), human dermal fibroblasts (PHDF) and human adipose-derived stem cells (ASCs) in vitro. All G/C/P biocomposites exhibited similar cell growth and mechanical characteristics in comparison with C/P biocomposites. G/C/P biocomposites with a lower collagen content showed better cell proliferation than those with a higher collagen content in vitro. Due to reasonable mechanical strength and biocompatibility in vitro, G/C/P with a lower content of collagen and a higher content of PCL (GCLPH) was selected for animal wound healing studies. According to our data, a significant promotion in wound healing and skin regeneration could be observed in GCLPH seeded with adipose-derived stem cells by Gomori's trichrome staining. CONCLUSIONS This study may provide an effective and low-cost wound dressings to assist skin regeneration for clinical use.

UI MeSH Term Description Entries

Related Publications

Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
December 2021, Drug development and industrial pharmacy,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
January 2021, Journal of bionic engineering,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
January 2014, Materials science & engineering. C, Materials for biological applications,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
August 2013, Biomedical materials (Bristol, England),
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
June 2022, Artificial organs,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
March 2024, Cureus,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
December 2018, RSC advances,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
March 2019, International journal of biological macromolecules,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
February 2021, Materials science & engineering. C, Materials for biological applications,
Lin-Gwei Wei, and Hsin-I Chang, and Yiwei Wang, and Shan-Hui Hsu, and Lien-Guo Dai, and Keng-Yen Fu, and Niann-Tzyy Dai
May 2022, Marine drugs,
Copied contents to your clipboard!